13 Best Multibagger Stocks to Invest in Now

4. Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Upside Potential:           489.89%

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a biotechnology company that specializes in developing cell and exosome-based therapies for muscular and other diseases. Its flagship therapeutic candidate, CAP-1002, is in advanced clinical stages and is designed to address Duchenne muscular dystrophy (DMD), a severe genetic disorder that primarily affects muscles and the heart. CAP-1002 utilizes cardiosphere-derived cells (CDCs), which have been shown to modulate the immune system and reduce harmful tissue buildup, known as fibrosis, in the heart. This unique approach underscores the company’s dedication to tackling complex medical conditions through innovative science.

In addition to its work on CAP-1002, Capricor is actively advancing its exosome platform, which harnesses the potential of extracellular vesicles for therapeutic applications. Collaborations with esteemed institutions such as the National Institutes of Health (NIH), the U.S. Army Institute of Surgical Research, Johns Hopkins University, and Cedars-Sinai Medical Center exemplify its commitment to advancing research and development. These partnerships aim to broaden the scope of Capricor’s initiatives, including the development of vaccines and therapeutics for infectious diseases and monogenic disorders.

Capricor Therapeutics has demonstrated financial strength and strategic foresight. For the fourth quarter of 2024, the company reported revenues of $11.13 million, contributing to a total of $25.4 million in annual revenue. This growth is attributed to its pioneering efforts in cell therapy programs. With $78 million in cash reserves, Capricor is well-equipped to support ongoing clinical trials and future commercialization efforts, ensuring sustainability in its ambitious endeavors.

In March, Reuters reported in an article Capricor Therapeutics (CAPR.O) announced that the U.S. Food and Drug Administration (FDA) intends to assemble a panel of external experts to review its cell therapy for a heart condition associated with Duchenne muscular dystrophy (DMD) before making a final decision. The company is pursuing full regulatory approval for its investigational cell therapy, deramiocel, as a potential treatment for patients with Duchenne muscular dystrophy cardiomyopathy. Following the news, the company’s shares dropped nearly 15%, reaching $10.11 in morning trading. Wall Street analysts, however, have taken a favorable view of Capricor’s prospects, recommending the stock as a “Strong Buy.” The consensus twelve-month price target as of May 13, 2025, stands at $43.71, reflecting a remarkable upside potential of 489.89%.